

Korea's Samsung Biologics to provide fill-finish manufacturing for Moderna COVID-19 vaccine

26 May 2021 | News

Upon execution of the deal, technology transfer will commence immediately at Samsung Biologics' facilities in Incheon, South Korea

Moderna and Samsung Biologics, a leading global CDMO providing a fully integrated end-to-end contract development and manufacturing service, have announced a Manufacturing Services and Supply Agreement in which South Korea-based Samsung Biologics will provide large scale, commercial fill-finish manufacturing for mRNA-1273, Moderna's COVID-19 vaccine.

Upon execution of the deal, technology transfer will commence immediately at Samsung Biologics' facilities in Incheon, South Korea, utilizing a state-of-the-art production line equipped for aseptic fill-finish, labeling, and packaging services to support the production of hundreds of millions of doses of Moderna's COVID-19 vaccine intended for the supply of markets outside of the U.S. starting in the third quarter of 2021.

"This vaccine is paramount to people around the world in the fight against the COVID-19 pandemic, and we truly appreciate our client Moderna for entrusting and choosing to partner with Samsung Biologics for the fill and finish of this important vaccine," said John Rim, CEO of Samsung Biologics. "Due to the high level of urgency in supplying the vaccine to the global population, we have set immediate action plans and schedule to make mRNA-1273 available for commercial distribution in the early second half of 2021."